IONIS PHARMACEUTICALS, INC.

Lobbying for IONIS PHARMACEUTICALS, INC. · Biotechnology company.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 15, 2026

Expenses

$150,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act.

Taxation/Internal Revenue Code

Issues related to the implementation of the Tax Cuts and Jobs Act of 2017. H.R.1414 - Camerons Law.

Bills named in this filing 4

H.R. 1672
Maintaining Investments in New Innovation Act
H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 932
Give Kids a Chance Act of 2025
H.R. 1414
Cameron’s Law

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.